BCL2 and lymphoma: In the phase Ib BO42203 trial, the addition of the oral BCL-2 inhibitor venetoclax (Ven) to the Pola-R-CHP regimen was evaluated in treatment-naïve, high-risk BCL-2 IHC-positive DLBCL patients, including those with double-hit and triple-hit lymphomas (DHL/THL).